


# Accepted Manuscript

Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome with Eluxadoline

Andrew J. Gawron, Klaus Bielefeldt



PII: S1542-3565(17)30935-7  
DOI: [10.1016/j.cgh.2017.08.006](https://doi.org/10.1016/j.cgh.2017.08.006)  
Reference: YJCGH 55386

To appear in: *Clinical Gastroenterology and Hepatology*  
Accepted Date: 4 August 2017

Please cite this article as: Gawron AJ, Bielefeldt K, Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome with Eluxadoline, *Clinical Gastroenterology and Hepatology* (2017), doi: 10.1016/j.cgh.2017.08.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome with Eluxadoline**

Andrew J. Gawron<sup>1,2,3</sup> & Klaus Bielefeldt<sup>1</sup>

<sup>1</sup>George E. Wahlen VA Medical Center, Salt Lake City Utah

<sup>2</sup>Division of Gastroenterology, Hepatology, and Nutrition, University of Utah, Salt Lake City

<sup>3</sup>Salt Lake City Specialty Care Center of Innovation, Salt Lake City Utah

Running Head: Eluxadoline and Pancreatitis

Address for Correspondence:

Klaus Bielefeldt, MD, PhD

George E. Wahlen VA Medical Center

Gastroenterology Section

500 Foothill Dr.

Salt Lake City, UT 84148

Email: [Klaus.bielefeldt@va.gov](mailto:Klaus.bielefeldt@va.gov)

**Conflict of Interest:** The authors do not have any conflict of interest to declare.

**Funding:** none

**Authorship Statement:** Klaus Bielefeldt is the guarantor of the manuscript. He designed the study, performed the data abstraction and analysis and drafted the manuscript. Andrew Gawron analyzed data and contributed to the writing of the manuscript. Both authors read and approved the final version of the manuscript.

**Abbreviations:** FDA – Food and Drug Administration; FAERS – Federal Adverse Event Reporting System; IBS – irritable bowel syndrome

Download English Version:

<https://daneshyari.com/en/article/8725197>

Download Persian Version:

<https://daneshyari.com/article/8725197>

[Daneshyari.com](https://daneshyari.com)